Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged ≥1 to <7 years with NF1-related Symptomatic, Inoperable PN

Trial Identifier: D1346C00004
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.
NCTID:: NCT05309668
Start Date: January 2022
Primary Completion Date: January 2024
Study Completion Date: October 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Berlin, Germany, 13353
Germany Hamburg, Germany, 20246
Germany Munchen, Germany, 80337
Germany Tubingen, Germany, 72076
Italy Milano, Italy, 20133
Italy Roma, Italy, 00165
Italy Torino, Italy, 10126
Japan Nagoya-shi, Japan, 466-8560
Japan Setagaya-ku, Japan, 157-8535
Japan Yufu-shi, Japan, 879-5593
Netherlands Rotterdam, Netherlands, 3015 GD
Russia Moscow, Russia, 125412
Russia Moscow, Russia, 119620
Spain Barcelona, Spain, 08950
USA, AZ Phoenix, AZ, USA, 85060
USA, IN Indianapolis, IN, USA, 46202
USA, OH Akron, OH, USA, 44308
USA, PA Philadelphia, PA, USA, 19104
USA, TX Houston, TX, USA, 77030
USA, VA Richmond, VA, USA, 23219